ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly share repurchase authorization remaining ($M) ($M)
Form 10-Q / 10-K Shareholders' Equity Note
Latest, Q2 2026
7,000
Period ended Jun 30, 2026
Change on a year earlier
-46.6%
13,110 in Q2 2025
History
39 quarters
Since Q1 2016
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Share repurchase authorization remaining ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7,000 | -46.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 8,600 | -37.7% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 10,900 | – | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 12,400 | +526.3% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 13,110 | +424.4% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 13,800 | +452.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,980 | -20.8% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,500 | 0.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,500 | 0.0% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,500 | -23.1% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,500 | -23.1% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,500 | -23.1% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,500 | -23.1% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,250 | -31.6% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,250 | +550.0% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,250 | +550.0% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,250 | +225.0% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,750 | +375.0% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 500 | -50.0% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2021 | Jun 30, 2021 | 500 | -50.0% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,000 | 0.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,000 | -33.3% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,000 | -44.4% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,000 | -58.3% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,000 | -67.7% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,500 | -74.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,800 | -74.3% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,400 | – | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,100 | +226.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,900 | +187.8% | Form 10-K (filed 2019-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,000 | +225.6% | Form 10-Q (filed 2018-11-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 951 | -59.5% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,050 | – | Form 10-K (filed 2018-02-20) ↗ |
| Q3 2017 | Sep 30, 2017 | 2,150 | -18.9% | Form 10-Q (filed 2017-10-27) ↗ |
| Q2 2017 | Jun 30, 2017 | 2,150 | -18.9% | Form 10-Q (filed 2017-07-28) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,350 | -11.3% | Form 10-Q (filed 2017-05-01) ↗ |
| Q3 2016 | Sep 30, 2016 | 2,650 | – | Form 10-Q (filed 2016-10-28) ↗ |
| Q2 2016 | Jun 30, 2016 | 2,650 | – | Form 10-Q (filed 2016-07-28) ↗ |
| Q1 2016 | Mar 31, 2016 | 2,650 | – | Form 10-Q (filed 2016-04-29) ↗ |
Cite this data
StockData. (2026). Eli Lilly Share repurchase authorization remaining ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/buyback_auth_remaining
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.